<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1542-9741" xmlns="http://purl.org/rss/1.0/"><title>Birth Defects Research Part B: Developmental and Reproductive Toxicology</title><description> Wiley Online Library : Birth Defects Research Part B: Developmental and Reproductive Toxicology</description><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2F%28ISSN%291542-9741</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Copyright © 2012 Wiley Periodicals, Inc.</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1542-9733</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1542-9741</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">April 2013</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">98</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">2</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">119</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">205</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/bdrb.2013.98.issue-2/asset/cover.gif?v=1&amp;s=560c6e94bfa02ddb833c253e05e1bce05b6fe2fe"/><items><rdf:Seq><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21063"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21062"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21061"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21058"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21057"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21055"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21036"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21037"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21050"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21051"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21052"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21053"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21054"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21056"/></rdf:Seq></items></channel><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21063" xmlns="http://purl.org/rss/1.0/"><title>Ethanol Alters Proliferation and Differentiation of Normal and Chromosomally Abnormal Human Embryonic Stem Cell-Derived Neurospheres</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21063</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ethanol Alters Proliferation and Differentiation of Normal and Chromosomally Abnormal Human Embryonic Stem Cell-Derived Neurospheres</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Malini Krishnamoorthy, Brian A. Gerwe, Christopher D. Scharer, Vanita Sahasranaman, Carmen D. Eilertson, Rachel J. Nash, Sümeyra Naz Usta, Shasmine Kelly, Matthew Rose, Rene Peraza, Jagan Arumugham, Bethany Stewart, Steven L. Stice, Rodney J. Nash</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-21T15:06:57.634142-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21063</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21063</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21063</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Ethanol is a powerful substance and, when consumed during pregnancy, has significant psychoactive and developmental effects on the developing fetus. These abnormalities include growth retardation, neurological deficits, and behavioral and cognitive deficiencies, commonly referred to as fetal alcohol spectrum disorder. The effect of ethanol has been reported to affect cellular development on the embryonic level, however, not much is known about mutations contributing to the influence of ethanol. The purpose of our study was to determine if mutation contribute to changes in differentiation patterning, cell-cycle regulatory gene expression, and DNA methylation in human embryonic stem cells after ethanol exposure. We exposed human embryonic stem cells (with and without know DNA mutations) to a low concentration (20 mM) of ethanol and measured neurosphere proliferation and differentiation, glial protein levels, expression of various cell-cycle genes, and DNA methylation. Ethanol altered cell-cycle gene expression between the two cell lines; however, gene methylation was not affected in ether lines. </p></div>]]></content:encoded><description>
Ethanol is a powerful substance and, when consumed during pregnancy, has significant psychoactive and developmental effects on the developing fetus. These abnormalities include growth retardation, neurological deficits, and behavioral and cognitive deficiencies, commonly referred to as fetal alcohol spectrum disorder. The effect of ethanol has been reported to affect cellular development on the embryonic level, however, not much is known about mutations contributing to the influence of ethanol. The purpose of our study was to determine if mutation contribute to changes in differentiation patterning, cell-cycle regulatory gene expression, and DNA methylation in human embryonic stem cells after ethanol exposure. We exposed human embryonic stem cells (with and without know DNA mutations) to a low concentration (20 mM) of ethanol and measured neurosphere proliferation and differentiation, glial protein levels, expression of various cell-cycle genes, and DNA methylation. Ethanol altered cell-cycle gene expression between the two cell lines; however, gene methylation was not affected in ether lines. </description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21062" xmlns="http://purl.org/rss/1.0/"><title>A Screen for Disruptors of the Retinol (Vitamin A) Signaling Pathway</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21062</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A Screen for Disruptors of the Retinol (Vitamin A) Signaling Pathway</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yanling Chen, David H. Reese</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-21T15:06:42.343454-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21062</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21062</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21062</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>The pathway through which retinol (vitamin A) is converted to its active metabolite, all-<em>trans</em>-retinoic acid (atRA), and subsequent receptor-mediated regulation of gene transcription by atRA is essential for all mammal life stages. This pathway is required for normal embryonic development and maintenance of cellular phenotype in adult organisms; chemicals that cause even minor interference with its normal function are potential developmental and adult toxicants. A short-term (24 h) in vitro mode-of-action screen for detecting chemicals that disrupt this essential pathway is described. It uses the mouse pluripotent P19 stem cell in a 96-well format, RT-qPCR gene-expression assay that does not require RNA purification to detect chemicals that interfere with retinol-induced <em>Hoxa1</em> gene expression, a target of retinol signaling in mammals. A total of 21 chemicals were screened at a single 45 μM concentration. Four chemicals known to disrupt the pathway in the rodent embryo (citral, disulfiram, and two rodent teratogens, nitrofen and bisdiamine) all significantly inhibited <em>Hoxa1</em> upregulation by retinol. An additional four of seven chemicals with varying degrees of structural similarity to known disruptors or to the retinoid side chain, but not previously known to disrupt the pathway, were positive in the screen. The xenoestrogens, diethylstilbestrol, bisphenol A, 4-<em>n</em>-nonylphenol, and genistein and the phthalate esters, dibutyl phthalate and dipentyl phthalate, but not diethylhexyl phthalate, also significantly disrupted the pathway. Of the 21 chemicals tested, diethylstilbestrol was the only chemical that showed evidence in the MTT assay that cytotoxicity may have contributed to disruption of the pathway.</p></div>]]></content:encoded><description>
The pathway through which retinol (vitamin A) is converted to its active metabolite, all-trans-retinoic acid (atRA), and subsequent receptor-mediated regulation of gene transcription by atRA is essential for all mammal life stages. This pathway is required for normal embryonic development and maintenance of cellular phenotype in adult organisms; chemicals that cause even minor interference with its normal function are potential developmental and adult toxicants. A short-term (24 h) in vitro mode-of-action screen for detecting chemicals that disrupt this essential pathway is described. It uses the mouse pluripotent P19 stem cell in a 96-well format, RT-qPCR gene-expression assay that does not require RNA purification to detect chemicals that interfere with retinol-induced Hoxa1 gene expression, a target of retinol signaling in mammals. A total of 21 chemicals were screened at a single 45 μM concentration. Four chemicals known to disrupt the pathway in the rodent embryo (citral, disulfiram, and two rodent teratogens, nitrofen and bisdiamine) all significantly inhibited Hoxa1 upregulation by retinol. An additional four of seven chemicals with varying degrees of structural similarity to known disruptors or to the retinoid side chain, but not previously known to disrupt the pathway, were positive in the screen. The xenoestrogens, diethylstilbestrol, bisphenol A, 4-n-nonylphenol, and genistein and the phthalate esters, dibutyl phthalate and dipentyl phthalate, but not diethylhexyl phthalate, also significantly disrupted the pathway. Of the 21 chemicals tested, diethylstilbestrol was the only chemical that showed evidence in the MTT assay that cytotoxicity may have contributed to disruption of the pathway.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21061" xmlns="http://purl.org/rss/1.0/"><title>Emodin Prevents Ethanol-Induced Developmental Anomalies in Cultured Mouse Fetus through Multiple Activities</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21061</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Emodin Prevents Ethanol-Induced Developmental Anomalies in Cultured Mouse Fetus through Multiple Activities</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jung-Min Yon, Chunmei Lin, Ki-Wan Oh, Hong-Seok Baek, Beom Jun Lee, Young Won Yun, Sang-Yoon Nam</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-21T15:06:35.146186-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21061</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21061</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21061</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Research Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="bdrb21061-sec-0010" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Maternal alcohol ingestion on pregnant period causes fetal alcohol syndrome including psychological and behavioral problems, and developmental abnormality. In this study, we investigated the effect of emodin, an active anthraquinone component found in the roots and bark of the genus <em>Rhamnus</em> (Buckthorn), on ethanol-induced teratogenesis during embryonic organogenesis.</p></div></div>
<div class="section" id="bdrb21061-sec-0020" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>We cultured mouse embryos on embryonic day 8.5 for 2 days with ethanol (5 μl/3 ml) and/or emodin (1×10<sup>−5</sup> and 1×10<sup>−4</sup> μg/ml) using a whole embryo culture system and then investigated the developmental evaluation, superoxide dismutase (SOD) activity, and expression patterns of cytoplasmic SOD (SOD1), mitochondrial SOD (SOD2), cytosolic glutathione peroxidase (cGPx), tumor necrosis factor-α (TNF-α), caspase 3, and hypoxia inducible factor 1α (HIF-1α).</p></div></div>
<div class="section" id="bdrb21061-sec-0030" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Morphological parameters, including growth in yolk sac and fetal head, body length, and development of the central nervous system, circulation system, sensory organs, skeletal system, and limbs in embryos exposed to ethanol were significantly decreased compared to those of the normal control group, but co-treatment with emodin (1 × 10<sup>−5</sup> and 1 × 10<sup>−4</sup> μg/ml) significantly improved these parameters. Furthermore, the reduced levels of SOD activity, and SOD1, SOD2, cGPx, and HIF-1α and the increased gene levels of TNF-α and caspase-3 due to ethanol exposure were significantly restored by cotreatment with emodin.</p></div></div>
<div class="section" id="bdrb21061-sec-0040" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>This study revealed that cotreatment with emodin significantly prevented teratogenesis induced by ethanol, not only by modulating hypoxia and antioxidant enzymes, but also by attenuating the enhanced levels of TNF-α and caspase 3 in cultured embryos. Therefore, emodin may be an effective preventive agent for ethanol-induced teratogenesis.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Maternal alcohol ingestion on pregnant period causes fetal alcohol syndrome including psychological and behavioral problems, and developmental abnormality. In this study, we investigated the effect of emodin, an active anthraquinone component found in the roots and bark of the genus Rhamnus (Buckthorn), on ethanol-induced teratogenesis during embryonic organogenesis.


METHODS
We cultured mouse embryos on embryonic day 8.5 for 2 days with ethanol (5 μl/3 ml) and/or emodin (1×10−5 and 1×10−4 μg/ml) using a whole embryo culture system and then investigated the developmental evaluation, superoxide dismutase (SOD) activity, and expression patterns of cytoplasmic SOD (SOD1), mitochondrial SOD (SOD2), cytosolic glutathione peroxidase (cGPx), tumor necrosis factor-α (TNF-α), caspase 3, and hypoxia inducible factor 1α (HIF-1α).


RESULTS
Morphological parameters, including growth in yolk sac and fetal head, body length, and development of the central nervous system, circulation system, sensory organs, skeletal system, and limbs in embryos exposed to ethanol were significantly decreased compared to those of the normal control group, but co-treatment with emodin (1 × 10−5 and 1 × 10−4 μg/ml) significantly improved these parameters. Furthermore, the reduced levels of SOD activity, and SOD1, SOD2, cGPx, and HIF-1α and the increased gene levels of TNF-α and caspase-3 due to ethanol exposure were significantly restored by cotreatment with emodin.


CONCLUSIONS
This study revealed that cotreatment with emodin significantly prevented teratogenesis induced by ethanol, not only by modulating hypoxia and antioxidant enzymes, but also by attenuating the enhanced levels of TNF-α and caspase 3 in cultured embryos. Therefore, emodin may be an effective preventive agent for ethanol-induced teratogenesis.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21058" xmlns="http://purl.org/rss/1.0/"><title>Species Differences in Developmental Toxicity of Epoxiconazole and Its Relevance to Humans</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21058</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Species Differences in Developmental Toxicity of Epoxiconazole and Its Relevance to Humans</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Steffen Schneider, Thomas Hofmann, Stefan Stinchcombe, Maria Cecilia Rey Moreno, Ivana Fegert, Volker Strauss, Sibylle Gröters, Eric Fabian, Jutta Thiaener, Karma C. Fussell, Bennard Ravenzwaay</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-29T13:11:59.900849-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21058</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21058</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21058</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Epoxiconazole, a triazole-based fungicide, was tested in toxicokinetic, prenatal and pre-postnatal toxicity studies in guinea pigs, following oral (gavage) administration at several dose levels (high dose: 90 mg/kg body weight per day). Maternal toxicity was evidenced by slightly increased abortion rates and by histopathological changes in adrenal glands, suggesting maternal stress. No compound-related increase in the incidence of malformations or variations was observed in the prenatal study. In the pre-postnatal study, epoxiconazole did not adversely affect gestation length, parturition, or postnatal growth and development. Administration of epoxiconazole did not alter circulating estradiol levels. Histopathological examination of the placentas did not reveal compound-related effects. The results in guinea pigs are strikingly different to those observed in pregnant rats, in which maternal estrogen depletion, pathological alteration of placentas, increased gestation length, late fetal death, and dystocia were observed after administration of epoxiconazole. In the studies reported here, analysis of maternal plasma concentrations and metabolism after administration of radiolabeled epoxiconazole demonstrated that the different results in rats and guinea pigs were not due to different exposures of the animals. A comprehensive comparison of hormonal regulation of pregnancy and birth in murid rodents and primates indicates that the effects on pregnancy and parturition observed in rats are not applicable to humans. In contrast, the pregnant guinea pig shares many similarities to pregnant humans regarding hormonal regulation and is therefore considered to be a suitable species for extrapolation of related effects to humans.</p></div>]]></content:encoded><description>
Epoxiconazole, a triazole-based fungicide, was tested in toxicokinetic, prenatal and pre-postnatal toxicity studies in guinea pigs, following oral (gavage) administration at several dose levels (high dose: 90 mg/kg body weight per day). Maternal toxicity was evidenced by slightly increased abortion rates and by histopathological changes in adrenal glands, suggesting maternal stress. No compound-related increase in the incidence of malformations or variations was observed in the prenatal study. In the pre-postnatal study, epoxiconazole did not adversely affect gestation length, parturition, or postnatal growth and development. Administration of epoxiconazole did not alter circulating estradiol levels. Histopathological examination of the placentas did not reveal compound-related effects. The results in guinea pigs are strikingly different to those observed in pregnant rats, in which maternal estrogen depletion, pathological alteration of placentas, increased gestation length, late fetal death, and dystocia were observed after administration of epoxiconazole. In the studies reported here, analysis of maternal plasma concentrations and metabolism after administration of radiolabeled epoxiconazole demonstrated that the different results in rats and guinea pigs were not due to different exposures of the animals. A comprehensive comparison of hormonal regulation of pregnancy and birth in murid rodents and primates indicates that the effects on pregnancy and parturition observed in rats are not applicable to humans. In contrast, the pregnant guinea pig shares many similarities to pregnant humans regarding hormonal regulation and is therefore considered to be a suitable species for extrapolation of related effects to humans.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21057" xmlns="http://purl.org/rss/1.0/"><title>Potential Teratogenicity of Methimazole: Exposure of Zebrafish Embryos to Methimazole Causes Similar Developmental Anomalies to Human Methimazole Embryopathy</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21057</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Potential Teratogenicity of Methimazole: Exposure of Zebrafish Embryos to Methimazole Causes Similar Developmental Anomalies to Human Methimazole Embryopathy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuta Komoike, Masato Matsuoka, Kenjiro Kosaki</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-29T13:11:45.542146-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21057</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21057</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21057</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>While methimazole (MMI) is widely used in the therapy for hyperthyroidism, several groups have reported that maternal exposure to MMI results in a variety of congenital anomalies, including choanal and esophageal atresia, iridic and retinal coloboma, and delayed neurodevelopment. Thus, adverse effects of maternal exposure to MMI on fetal development have long been suggested; however, direct evidence for the teratogenicity of MMI has not been presented. Therefore, we studied the effects of MMI on early development by using zebrafish as a model organism. The fertilized eggs of zebrafish were collected immediately after spawning and grown in egg culture water containing MMI at various concentrations. External observation of the embryos revealed that exposure to high concentrations of MMI resulted in loss of pigmentation, hypoplastic hindbrain, turbid tissue in the forebrain, swelling of the notochord, and curly trunk. Furthermore, these effects occurred in a dose-dependent manner. Precise observation of the serial cross-sections of MMI-exposed embryos elucidated delayed development and hypoplasia of the whole brain and spinal cord, narrowing of the pharynx and esophagus, severe disruption of the retina, and aberrant structure of the notochord. These neuronal, pharyngeal, esophageal, and retinal anomalous morphologies have a direct analogy to the congenital anomalies observed in children exposed to MMI in utero. Here, we show the teratogenic effects of MMI on the development of zebrafish and provide the first experimental evidence for the connection between exposure to MMI and human MMI embryopathy.</p></div>]]></content:encoded><description>
While methimazole (MMI) is widely used in the therapy for hyperthyroidism, several groups have reported that maternal exposure to MMI results in a variety of congenital anomalies, including choanal and esophageal atresia, iridic and retinal coloboma, and delayed neurodevelopment. Thus, adverse effects of maternal exposure to MMI on fetal development have long been suggested; however, direct evidence for the teratogenicity of MMI has not been presented. Therefore, we studied the effects of MMI on early development by using zebrafish as a model organism. The fertilized eggs of zebrafish were collected immediately after spawning and grown in egg culture water containing MMI at various concentrations. External observation of the embryos revealed that exposure to high concentrations of MMI resulted in loss of pigmentation, hypoplastic hindbrain, turbid tissue in the forebrain, swelling of the notochord, and curly trunk. Furthermore, these effects occurred in a dose-dependent manner. Precise observation of the serial cross-sections of MMI-exposed embryos elucidated delayed development and hypoplasia of the whole brain and spinal cord, narrowing of the pharynx and esophagus, severe disruption of the retina, and aberrant structure of the notochord. These neuronal, pharyngeal, esophageal, and retinal anomalous morphologies have a direct analogy to the congenital anomalies observed in children exposed to MMI in utero. Here, we show the teratogenic effects of MMI on the development of zebrafish and provide the first experimental evidence for the connection between exposure to MMI and human MMI embryopathy.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21055" xmlns="http://purl.org/rss/1.0/"><title>Epoxiconazole-Induced Degeneration in Rat Placenta and the Effects of Estradiol Supplementation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21055</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Epoxiconazole-Induced Degeneration in Rat Placenta and the Effects of Estradiol Supplementation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Cecilia Rey Moreno, Karma C. Fussell, Sibylle Gröters, Steffen Schneider, Volker Strauss, Stefan Stinchcombe, Ivana Fegert, Mariana Veras, Bennard Ravenzwaay</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-29T13:11:29.403805-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21055</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21055</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21055</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Epoxiconazole (CAS-No. 133855-98-8) was recently shown to cause both a marked depletion of maternal estradiol blood levels and a significantly increased incidence of late fetal mortality when administered to pregnant rats throughout gestation (GD 7–18 or 21); estradiol supplementation prevented this epoxiconazole effect in rats (Stinchcombe et al., 2013), indicating that epoxiconazole-mediated estradiol depletion is a critical key event for induction of late fetal resorptions in rats. For further elucidation of the mode of action, the placentas from these modified prenatal developmental toxicity experiments with 23 and 50 mg/kg bw/d epoxiconazole were subjected to a detailed histopathological examination. This revealed dose-dependent placental degeneration characterized by cystic dilation of maternal sinuses in the labyrinth, leading to rupture of the interhemal membrane. Concomitant degeneration occurred in the trophospongium. Both placentas supporting live fetuses and late fetal resorptions were affected; the highest degree of severity was observed in placentas with late resorptions. Placental degeneration correlated with a severe decline in maternal serum estradiol concentration. Supplementation with 0.5 and 1.0 μg of the synthetic estrogen estradiol cyclopentylpropionate per day reduced the severity of the degeneration in placentas with live fetuses. The present study demonstrates that both the placental degeneration and the increased incidence of late fetal resorptions are due to decreased levels of estrogen, since estrogen supplementation ameliorates the former and abolishes the latter.</p></div>]]></content:encoded><description>
Epoxiconazole (CAS-No. 133855-98-8) was recently shown to cause both a marked depletion of maternal estradiol blood levels and a significantly increased incidence of late fetal mortality when administered to pregnant rats throughout gestation (GD 7–18 or 21); estradiol supplementation prevented this epoxiconazole effect in rats (Stinchcombe et al., 2013), indicating that epoxiconazole-mediated estradiol depletion is a critical key event for induction of late fetal resorptions in rats. For further elucidation of the mode of action, the placentas from these modified prenatal developmental toxicity experiments with 23 and 50 mg/kg bw/d epoxiconazole were subjected to a detailed histopathological examination. This revealed dose-dependent placental degeneration characterized by cystic dilation of maternal sinuses in the labyrinth, leading to rupture of the interhemal membrane. Concomitant degeneration occurred in the trophospongium. Both placentas supporting live fetuses and late fetal resorptions were affected; the highest degree of severity was observed in placentas with late resorptions. Placental degeneration correlated with a severe decline in maternal serum estradiol concentration. Supplementation with 0.5 and 1.0 μg of the synthetic estrogen estradiol cyclopentylpropionate per day reduced the severity of the degeneration in placentas with live fetuses. The present study demonstrates that both the placental degeneration and the increased incidence of late fetal resorptions are due to decreased levels of estrogen, since estrogen supplementation ameliorates the former and abolishes the latter.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21036" xmlns="http://purl.org/rss/1.0/"><title>A Review of Developmental and Reproductive Toxicity of CS2 and H2S Generated by the Pesticide Sodium Tetrathiocarbonate</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21036</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A Review of Developmental and Reproductive Toxicity of CS2 and H2S Generated by the Pesticide Sodium Tetrathiocarbonate</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marilyn Silva</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-15T11:25:35.035273-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21036</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21036</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21036</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Review Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">119</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">138</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="bdrb21036-sec-0010" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Sodium tetrathiocarbonate (STTC) is an example of a pesticide that when prepared for use in aqueous solution releases two toxic products carbon disulfide (CS<sub>2</sub>) (active ingredient) and hydrogen sulfide (H<sub>2</sub>S) in ambient air in equimolar concentrations resulting in potential exposure to workers and bystanders. CS<sub>2</sub> and H<sub>2</sub>S are pollutants that are generated from several pesticides as well as in industrial settings.</p></div></div>
<div class="section" id="bdrb21036-sec-0020" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Registrant submitted reports and open literature studies for STTC, CS<sub>2</sub> and H<sub>2</sub>S were reviewed. Previous reports suggest that CS<sub>2</sub> was a concern as a developmental and reproductive toxicant. H<sub>2</sub>S was also examined since it is a neurotoxicant and potentially harmful to developing fetuses.</p></div></div>
<div class="section" id="bdrb21036-sec-0030" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>STTC did not induce developmental or reproductive effects in animal studies. CS<sub>2</sub> was a developmental neurobehavioral toxin in rat pups (inhalation no observed effect level [NOEL] = 0.01ppm). Reproductive effects occurred in male and female factory workers after CS<sub>2</sub> exposure (NOEL = 1ppm). H<sub>2</sub>S had developmental effects in rats at doses at or above those observed for nasal pathology (NOEL = 10ppm) but was not a reproductive or developmental toxin in humans.</p></div></div>
<div class="section" id="bdrb21036-sec-0040" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>The database for CS<sub>2</sub> indicates a strong potential for developmental neurotoxicity in animals at low doses but it is lacking in acceptable, well-performed studies. There is also a lack of studies performed with CS<sub>2</sub> and H<sub>2</sub>S as a mixture.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Sodium tetrathiocarbonate (STTC) is an example of a pesticide that when prepared for use in aqueous solution releases two toxic products carbon disulfide (CS2) (active ingredient) and hydrogen sulfide (H2S) in ambient air in equimolar concentrations resulting in potential exposure to workers and bystanders. CS2 and H2S are pollutants that are generated from several pesticides as well as in industrial settings.


METHODS
Registrant submitted reports and open literature studies for STTC, CS2 and H2S were reviewed. Previous reports suggest that CS2 was a concern as a developmental and reproductive toxicant. H2S was also examined since it is a neurotoxicant and potentially harmful to developing fetuses.


RESULTS
STTC did not induce developmental or reproductive effects in animal studies. CS2 was a developmental neurobehavioral toxin in rat pups (inhalation no observed effect level [NOEL] = 0.01ppm). Reproductive effects occurred in male and female factory workers after CS2 exposure (NOEL = 1ppm). H2S had developmental effects in rats at doses at or above those observed for nasal pathology (NOEL = 10ppm) but was not a reproductive or developmental toxin in humans.


CONCLUSIONS
The database for CS2 indicates a strong potential for developmental neurotoxicity in animals at low doses but it is lacking in acceptable, well-performed studies. There is also a lack of studies performed with CS2 and H2S as a mixture.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21037" xmlns="http://purl.org/rss/1.0/"><title>Decreased Expression of GATA4 in the Diaphragm of Nitrofen-Induced Congenital Diaphragmatic Hernia</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21037</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Decreased Expression of GATA4 in the Diaphragm of Nitrofen-Induced Congenital Diaphragmatic Hernia</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jens Dingemann, Takashi Doi, Jan-Hendrik Gosemann, Elke Maria Ruttenstock, Nana Nakazawa, Prem Puri</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-19T00:00:00-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21037</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21037</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21037</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">139</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">143</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="bdrb21037-sec-0010" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>The molecular mechanisms underlying the diaphragmatic defect in congenital diaphragmatic hernia (CDH) are still poorly understood. The transcription factor GATA4 is essential for normal development of the diaphragm. Recently, mutations in the GATA4 gene have been linked to human and rodent CDH. We hypothesized that diaphragmatic GATA4 expression is downregulated in the nitrofen CDH model.</p></div></div>
<div class="section" id="bdrb21037-sec-0020" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Pregnant rats received Nitrofen or vehicle on day 9 of gestation (D9). Fetuses were sacrificed on D13, D18, or D21. Pleuroperitoneal folds (<em>n</em> = 20) and fetal diaphragms (<em>n</em> = 40) were (micro) dissected and divided into CDH group and controls. RNA and protein were extracted. GATA4 mRNA levels were determined by real-time PCR. Protein levels were determined by ELISA and Immunohistochemistry.</p></div></div>
<div class="section" id="bdrb21037-sec-0030" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>mRNA levels and Protein levels were significantly decreased in the CDH group compared to controls on D13 (mRNA 15.96 ± 6.99 vs. 38.10 ± 5.01, <em>p</em> &lt; 0.05), D18 (mRNA 10.45 ± 1.84 vs. 17.68 ± 2.11, Protein 2.59 ± 0.06 vs. 4.58 ± 0.35 <em>p</em> &lt; 0.05) and D21 (mRNA 4.31 ± 0.83 vs. 6.87 ± 0.88, Protein 0.16 ± 0.08 vs. 1.26 ± 0.49, <em>p</em> &lt; 0.05). Immunoreactivity of GATA4 was markedly decreased in CDH-diaphragms on D13, D18, and D21.</p></div></div>
<div class="section" id="bdrb21037-sec-0040" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>We provide evidence for the first time that diaphragmatic expression of GATA4 is downregulated in the nitrofen model, suggesting that decreased expression of GATA4 may impair diaphragmatic development in nitrofen-induced CDH.</p></div></div>
]]></content:encoded><description>

BACKGROUND
The molecular mechanisms underlying the diaphragmatic defect in congenital diaphragmatic hernia (CDH) are still poorly understood. The transcription factor GATA4 is essential for normal development of the diaphragm. Recently, mutations in the GATA4 gene have been linked to human and rodent CDH. We hypothesized that diaphragmatic GATA4 expression is downregulated in the nitrofen CDH model.


METHODS
Pregnant rats received Nitrofen or vehicle on day 9 of gestation (D9). Fetuses were sacrificed on D13, D18, or D21. Pleuroperitoneal folds (n = 20) and fetal diaphragms (n = 40) were (micro) dissected and divided into CDH group and controls. RNA and protein were extracted. GATA4 mRNA levels were determined by real-time PCR. Protein levels were determined by ELISA and Immunohistochemistry.


RESULTS
mRNA levels and Protein levels were significantly decreased in the CDH group compared to controls on D13 (mRNA 15.96 ± 6.99 vs. 38.10 ± 5.01, p &lt; 0.05), D18 (mRNA 10.45 ± 1.84 vs. 17.68 ± 2.11, Protein 2.59 ± 0.06 vs. 4.58 ± 0.35 p &lt; 0.05) and D21 (mRNA 4.31 ± 0.83 vs. 6.87 ± 0.88, Protein 0.16 ± 0.08 vs. 1.26 ± 0.49, p &lt; 0.05). Immunoreactivity of GATA4 was markedly decreased in CDH-diaphragms on D13, D18, and D21.


CONCLUSIONS
We provide evidence for the first time that diaphragmatic expression of GATA4 is downregulated in the nitrofen model, suggesting that decreased expression of GATA4 may impair diaphragmatic development in nitrofen-induced CDH.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21050" xmlns="http://purl.org/rss/1.0/"><title>The Teratogenic Effect of Dofetilide during Rat Limb Development and Association with Drug-Induced Bradycardia and Hypoxia in the Embryo</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21050</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The Teratogenic Effect of Dofetilide during Rat Limb Development and Association with Drug-Induced Bradycardia and Hypoxia in the Embryo</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Helen E. Ritchie, Deena H. Ababneh, Diana J. Oakes, Carl A. Power, William S. Webster</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-15T11:24:46.733501-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21050</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21050</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21050</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">144</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">153</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="bdrb21050-sec-0010" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Dofetilide is an antiarrhythmic drug that blocks the cardiac repolarizing current <em>I</em><sub>Kr</sub> ((<em>I</em><sub>Kr</sub>, rapid component of the delayed rectifying potassium current). Previous studies have shown that (a) <em>I</em><sub>Kr</sub> is essential for normal cardiac function of the embryonic heart and (b) dofetilide is teratogenic in rodents. This study was undertaken to examine the mechanism by which dofetilide causes limb defects on gestational day 13 (GD 13) in the rat.</p></div></div>
<div class="section" id="bdrb21050-sec-0020" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>Rats were treated with dofetilide (single oral dose, 5 mg/kg) on GD 13 and embryonic heart rates assessed by ultrasound (Vevo770, VisualSonics, Toronto, Ontario, Canada) 2 hr later. Fetuses were examined for malformations on GD 20. In a separate experiment, dofetilide treatment of GD 13 rats was followed 2, 4, 12, or 24 hr with iv dosing with the hypoxia marker, pimonidazole (60 mg/kg). Embryos were collected and heart rates were assessed in vitro and hypoxia in embryo limbs analyzed.</p></div></div>
<div class="section" id="bdrb21050-sec-0030" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>A teratogenic dose of dofetilide at a susceptible stage of development (GD 13) resulted in a period of bradycardia and arrhythmia of the embryonic heart and hypoxia in the developing limbs (GD 13) resulting in limb malformations (GD 20).</p></div></div>
<div class="section" id="bdrb21050-sec-0040" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>Drugs that induce periods of bradycardia and/or arrhythmia of the embryonic heart and cause the embryo to become hypoxic are potential human teratogens.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Dofetilide is an antiarrhythmic drug that blocks the cardiac repolarizing current IKr ((IKr, rapid component of the delayed rectifying potassium current). Previous studies have shown that (a) IKr is essential for normal cardiac function of the embryonic heart and (b) dofetilide is teratogenic in rodents. This study was undertaken to examine the mechanism by which dofetilide causes limb defects on gestational day 13 (GD 13) in the rat.


METHODS
Rats were treated with dofetilide (single oral dose, 5 mg/kg) on GD 13 and embryonic heart rates assessed by ultrasound (Vevo770, VisualSonics, Toronto, Ontario, Canada) 2 hr later. Fetuses were examined for malformations on GD 20. In a separate experiment, dofetilide treatment of GD 13 rats was followed 2, 4, 12, or 24 hr with iv dosing with the hypoxia marker, pimonidazole (60 mg/kg). Embryos were collected and heart rates were assessed in vitro and hypoxia in embryo limbs analyzed.


RESULTS
A teratogenic dose of dofetilide at a susceptible stage of development (GD 13) resulted in a period of bradycardia and arrhythmia of the embryonic heart and hypoxia in the developing limbs (GD 13) resulting in limb malformations (GD 20).


CONCLUSIONS
Drugs that induce periods of bradycardia and/or arrhythmia of the embryonic heart and cause the embryo to become hypoxic are potential human teratogens.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21051" xmlns="http://purl.org/rss/1.0/"><title>Cancer Risks in Parents Who had a Child with a Congenital Malformation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21051</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cancer Risks in Parents Who had a Child with a Congenital Malformation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuelian Sun, Kim Overvad, Wei Jin Zhou, Jin Liang Zhu, Jørn Olsen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-19T16:59:22.93183-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21051</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21051</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21051</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">154</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">163</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Cancer risk in parents may be related to congenital malformations (CMs) in their children if they share genetic susceptibility or environmental exposure that may be teratogenic and carcinogenic. We conducted a population-based cohort study based on Danish register data. We identified 795,607 mothers and 781,424 fathers who had all their children between 1977 and 2007 in Denmark. Information on CM was obtained from the Danish Hospital Registry and information on cancer was obtained from the Danish Cancer Registry. Parents were followed from the birth of their first child until the diagnosis of cancer, death, emigration, or December 31, 2007. We used Cox regression models to estimate hazard ratios (HRs) for cancer including cancer in specific organs in mothers and fathers. Overall, 75,701 (9.5%) mothers and 72,724 (9.3%) fathers had at least one child diagnosed with CMs within the first year of life. Neither mothers (HR = 1.04; 95% CI: 0.99–1.04) nor fathers (HR = 1.03; 95% CI: 0.98–1.09) who had a child with a CM had a higher overall risk of cancer. Mothers (HR = 0.76, 95% CI: 0.58–1.00) or fathers (HR = 0.89, 95% CI: 0.66–1.19) who had a child with a chromosomal malformation had a lower overall cancer risk. The findings also showed a higher risk for some specific types of cancer in parents who had children with a CM in the specific system. Some, or perhaps all, of these findings may be due to chance caused by multiple comparisons. We present all results on paper or online to provide clues for further research and to avoid publication bias.</p></div>]]></content:encoded><description>
Cancer risk in parents may be related to congenital malformations (CMs) in their children if they share genetic susceptibility or environmental exposure that may be teratogenic and carcinogenic. We conducted a population-based cohort study based on Danish register data. We identified 795,607 mothers and 781,424 fathers who had all their children between 1977 and 2007 in Denmark. Information on CM was obtained from the Danish Hospital Registry and information on cancer was obtained from the Danish Cancer Registry. Parents were followed from the birth of their first child until the diagnosis of cancer, death, emigration, or December 31, 2007. We used Cox regression models to estimate hazard ratios (HRs) for cancer including cancer in specific organs in mothers and fathers. Overall, 75,701 (9.5%) mothers and 72,724 (9.3%) fathers had at least one child diagnosed with CMs within the first year of life. Neither mothers (HR = 1.04; 95% CI: 0.99–1.04) nor fathers (HR = 1.03; 95% CI: 0.98–1.09) who had a child with a CM had a higher overall risk of cancer. Mothers (HR = 0.76, 95% CI: 0.58–1.00) or fathers (HR = 0.89, 95% CI: 0.66–1.19) who had a child with a chromosomal malformation had a lower overall cancer risk. The findings also showed a higher risk for some specific types of cancer in parents who had children with a CM in the specific system. Some, or perhaps all, of these findings may be due to chance caused by multiple comparisons. We present all results on paper or online to provide clues for further research and to avoid publication bias.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21052" xmlns="http://purl.org/rss/1.0/"><title>Effect of PPARβ/δ Agonist on the Placentation and Embryo-Fetal Development in Rats</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21052</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effect of PPARβ/δ Agonist on the Placentation and Embryo-Fetal Development in Rats</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kyohei Nishimura, Nao Nakano, Vishwajit Sur Chowdhury, Masako Kaneto, Mikinori Torii, Masa-aki Hattori, Nobuhiko Yamauchi, Motoyuki Kawai</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-04T17:48:56.828416-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21052</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21052</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21052</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">164</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">169</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="bdrb21052-sec-0010" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>The present study was conducted to evaluate the developmental toxicity in the endometrium and placenta due to GW501516 administration by gavage to pregnant rats.</p></div></div>
<div class="section" id="bdrb21052-sec-0020" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>GW501516 was orally administered repeatedly to pregnant rats from gestation day (GD) 6 to 17 at a dose of 0, 30, and 100 mg/kg/day. In next study, GW501516 was also orally administered to pregnant rats on GD 7, 8, 9, 10, or 11 at a single dose of 275 or 350 mg/kg. In these studies, caesarean section was performed to examine the pregnancy outcome on GD21. Additionally, GW501516 was orally administered to pregnant rats on GD 10 at a single dose of 275 mg/kg. Placentae were subjected for temporal histological examinations on GD 11, 13, 15, or 17.</p></div></div>
<div class="section" id="bdrb21052-sec-0030" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>Placental malformation was induced by repeated administration of GW501516 at a dose of 100 mg/kg/day. Single oral administration of GW501516 at a dose of 275 and/or 350 mg/kg on GD 8, 9, 10, or 11 induced placental malformation, whereas GW501516 administered on GD 10 was the most effective for increasing placental malformation. Histopathologically, single oral administration of GW501516 on GD 10 induced cystic degeneration associated with cellular lysis of glycogen cells started from GD 15 in the basal zone.</p></div></div>
<div class="section" id="bdrb21052-sec-0040" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>High frequency of placental malformation was observed by the administration of GW501516. From GD 8 to 11, especially GD 10, is more sensitive period to induce the placental malformation.</p></div></div>
]]></content:encoded><description>

BACKGROUND
The present study was conducted to evaluate the developmental toxicity in the endometrium and placenta due to GW501516 administration by gavage to pregnant rats.


METHODS
GW501516 was orally administered repeatedly to pregnant rats from gestation day (GD) 6 to 17 at a dose of 0, 30, and 100 mg/kg/day. In next study, GW501516 was also orally administered to pregnant rats on GD 7, 8, 9, 10, or 11 at a single dose of 275 or 350 mg/kg. In these studies, caesarean section was performed to examine the pregnancy outcome on GD21. Additionally, GW501516 was orally administered to pregnant rats on GD 10 at a single dose of 275 mg/kg. Placentae were subjected for temporal histological examinations on GD 11, 13, 15, or 17.


RESULTS
Placental malformation was induced by repeated administration of GW501516 at a dose of 100 mg/kg/day. Single oral administration of GW501516 at a dose of 275 and/or 350 mg/kg on GD 8, 9, 10, or 11 induced placental malformation, whereas GW501516 administered on GD 10 was the most effective for increasing placental malformation. Histopathologically, single oral administration of GW501516 on GD 10 induced cystic degeneration associated with cellular lysis of glycogen cells started from GD 15 in the basal zone.


CONCLUSIONS
High frequency of placental malformation was observed by the administration of GW501516. From GD 8 to 11, especially GD 10, is more sensitive period to induce the placental malformation.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21053" xmlns="http://purl.org/rss/1.0/"><title>The Effects of Interleukin-6 Signal Blockade on Immune System, Reproductive and Skeletal Development in Juvenile Mice</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21053</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The Effects of Interleukin-6 Signal Blockade on Immune System, Reproductive and Skeletal Development in Juvenile Mice</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takayuki Sakurai, Ryo Takai, Heinrich Bürgin, Akifumi Shioda, Yuichiro Sakamoto, Jun Amano, Hans Peter Grimm, Wolfgang F. Richter, Yoshinobu Higuchi, Shuichi Chiba, Akinori Kawamura, Masami Suzuki, Lutz Müller</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-25T13:35:35.108089-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21053</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21053</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21053</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">170</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">182</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Interleukin-6 (IL-6) is involved in the pathogenesis of multiple disorders, including juvenile autoimmune diseases. IL-6 participates in a broad spectrum of physiological events, and the IL-6 receptor (IL-6R) is widely distributed across multiple organs. The interrelationship of development phases in juveniles together with organs involved in IL-6 signaling called for evaluations of anti–IL-6R antibody induced effects in a juvenile mouse model to assess the safety of such an approach in human juvenile arthritis. Here we show that naive mice in which IL-6 signals have been transiently blocked during the juvenile period develop normally. The fatal immunogenic reactions recorded earlier by repeated administration of the chosen rat anti-mouse IL-6R antibody, MR16-1, to mice were avoided successfully by application of a high loading dose followed by lower maintenance doses, with the support of modeling data. The high loading-dose regimen enabled us to conduct assessments without any major interference due to immunogenicity. Transient and complete inhibition of IL-6 signals from postnatal days 22 to 79 in mice exhibited no biologically important changes in sexual maturation or development of immune and skeletal systems. Although tendencies toward reductions of peripheral blood T-cell counts were observed, normal levels of antigen-specific IgG/IgM antibody productions indicating sufficient immunological functions were confirmed. Our results demonstrate that blockage of IL-6R by the neutralizing antibody does not affect juvenile development. This may be in part due to the generation or existence of compensatory pathways in the whole body system.</p></div>]]></content:encoded><description>
Interleukin-6 (IL-6) is involved in the pathogenesis of multiple disorders, including juvenile autoimmune diseases. IL-6 participates in a broad spectrum of physiological events, and the IL-6 receptor (IL-6R) is widely distributed across multiple organs. The interrelationship of development phases in juveniles together with organs involved in IL-6 signaling called for evaluations of anti–IL-6R antibody induced effects in a juvenile mouse model to assess the safety of such an approach in human juvenile arthritis. Here we show that naive mice in which IL-6 signals have been transiently blocked during the juvenile period develop normally. The fatal immunogenic reactions recorded earlier by repeated administration of the chosen rat anti-mouse IL-6R antibody, MR16-1, to mice were avoided successfully by application of a high loading dose followed by lower maintenance doses, with the support of modeling data. The high loading-dose regimen enabled us to conduct assessments without any major interference due to immunogenicity. Transient and complete inhibition of IL-6 signals from postnatal days 22 to 79 in mice exhibited no biologically important changes in sexual maturation or development of immune and skeletal systems. Although tendencies toward reductions of peripheral blood T-cell counts were observed, normal levels of antigen-specific IgG/IgM antibody productions indicating sufficient immunological functions were confirmed. Our results demonstrate that blockage of IL-6R by the neutralizing antibody does not affect juvenile development. This may be in part due to the generation or existence of compensatory pathways in the whole body system.</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21054" xmlns="http://purl.org/rss/1.0/"><title>Neurotoxicity Assessment of Artemether in Juvenile Rats</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21054</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Neurotoxicity Assessment of Artemether in Juvenile Rats</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David A. Beckman, Maureen Youreneff, Mark T. Butt</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-11T15:27:22.57364-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21054</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21054</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21054</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">183</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">199</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="section" id="bdrb21054-sec-0010" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><h4>BACKGROUND</h4><div class="para"><p>Oral administration of artemether in combination with lumefantrine is approved for the treatment of malaria in adults and children. In adult animals, artemether can produce neurotoxicity with intramuscular, but not oral, administration. Herein, the potential of orally administered artemether to produce neurotoxicity in juvenile rats was investigated.</p></div></div>
<div class="section" id="bdrb21054-sec-0020" xmlns="http://www.w3.org/1999/xhtml"><h4>METHODS</h4><div class="para"><p>In the first study, the toxicity of artemether was evaluated in juvenile rats dosed with 0, 10, 30, and 100mg/kg/day on postpartum days (ppds) 7 to 21. In-life, clinical pathology, anatomic pathology, behavioral, and toxicokinetics evaluations were performed. The second study focused on neurotoxicity during different dosing intervals, with doses of 0, 30, and 80mg/kg/day on ppds 7 to 13, and doses of 0, 30, and 120mg/kg/day on ppds 14 to 21, 22 to 28, and 29 to 36. For each dosing interval, in-life, extensive histology, toxicokinetics, and behavioral evaluations were performed. In the third study, toxicokinetics evaluations in the adult were conducted at 20 and 200mg/kg/day.</p></div></div>
<div class="section" id="bdrb21054-sec-0030" xmlns="http://www.w3.org/1999/xhtml"><h4>RESULTS</h4><div class="para"><p>The first study demonstrated increased mortality, renal necrosis, and brain hemorrhage at ≥30mg/kg/day with no persistent effects in surviving animals. In the second study, increased mortality, body weight effects, and a trend toward increased exposure were observed in the ppd 14 and younger animals. Neither specific neurotoxicity nor persistent effects were seen. The toxicokinetic study in adults revealed lower exposures as compared to those in the younger juvenile rats.</p></div></div>
<div class="section" id="bdrb21054-sec-0040" xmlns="http://www.w3.org/1999/xhtml"><h4>CONCLUSIONS</h4><div class="para"><p>As in the adult rat, oral administration of artemether in the juvenile rat is not associated with the neurotoxicity produced by intramuscular administration.</p></div></div>
]]></content:encoded><description>

BACKGROUND
Oral administration of artemether in combination with lumefantrine is approved for the treatment of malaria in adults and children. In adult animals, artemether can produce neurotoxicity with intramuscular, but not oral, administration. Herein, the potential of orally administered artemether to produce neurotoxicity in juvenile rats was investigated.


METHODS
In the first study, the toxicity of artemether was evaluated in juvenile rats dosed with 0, 10, 30, and 100mg/kg/day on postpartum days (ppds) 7 to 21. In-life, clinical pathology, anatomic pathology, behavioral, and toxicokinetics evaluations were performed. The second study focused on neurotoxicity during different dosing intervals, with doses of 0, 30, and 80mg/kg/day on ppds 7 to 13, and doses of 0, 30, and 120mg/kg/day on ppds 14 to 21, 22 to 28, and 29 to 36. For each dosing interval, in-life, extensive histology, toxicokinetics, and behavioral evaluations were performed. In the third study, toxicokinetics evaluations in the adult were conducted at 20 and 200mg/kg/day.


RESULTS
The first study demonstrated increased mortality, renal necrosis, and brain hemorrhage at ≥30mg/kg/day with no persistent effects in surviving animals. In the second study, increased mortality, body weight effects, and a trend toward increased exposure were observed in the ppd 14 and younger animals. Neither specific neurotoxicity nor persistent effects were seen. The toxicokinetic study in adults revealed lower exposures as compared to those in the younger juvenile rats.


CONCLUSIONS
As in the adult rat, oral administration of artemether in the juvenile rat is not associated with the neurotoxicity produced by intramuscular administration.

</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21056" xmlns="http://purl.org/rss/1.0/"><title>The Effects of Shipping on Early Pregnancy in Laboratory Rats</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21056</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The Effects of Shipping on Early Pregnancy in Laboratory Rats</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kathleen R. Pritchett-Corning, Charles B. Clifford, Michael F. W. Festing</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-21T15:28:07.507043-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/bdrb.21056</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/bdrb.21056</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fbdrb.21056</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">200</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">205</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<div class="para" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib" xmlns="http://www.w3.org/1999/xhtml"><p>Although rats in various stages of pregnancy are routinely shipped by vendors, the effects of shipping on pregnancy outcomes have not been reported. This study examined the effects of shipping rats 1 day after mating. Two outbred stocks, (Crl:CD(SD), Crl:WI(Han)) and one inbred strain (F344/Crl) of rats (<em>n</em> = 300/strain) were mated in a vendor barrier room at 3-month intervals five times, and either shipped the next day (total time in transit ∼24 hr) or held in the room of origin until parturition. The pregnancy status, length of gestation, number of pups born per female, sex ratio of pups born, and neonatal mortality were compared between transported and nontransported rats. These pregnancy and litter parameters were also compared among strains and examined for seasonality; no seasonal effects were observed. Neonatal mortality was negligible at less than 2% in any of the groups. All sex ratios were normal. Transportation affected pregnancy rates only in the F344/Crl, in which 81.8% of the nontransported versus 70% of the transported rats had pups (<em>p</em> = 0.025). Overall, slightly fewer transported rats were pregnant, but they had larger litters (10.08 compared with 9.68, <em>p</em> = 0.02, pooling across all three strains) so produced the same numbers of pups. A total of 77 ± 8% of transported rats had gestation periods of 22 days or more compared with only 52 ± 10% in the nontransported rats. The reason for larger litters in transported females is unclear. Longer gestation in transported females may be due to facultative embryonic diapause, which might have implications for reproductive toxicology.</p></div>]]></content:encoded><description>
Although rats in various stages of pregnancy are routinely shipped by vendors, the effects of shipping on pregnancy outcomes have not been reported. This study examined the effects of shipping rats 1 day after mating. Two outbred stocks, (Crl:CD(SD), Crl:WI(Han)) and one inbred strain (F344/Crl) of rats (n = 300/strain) were mated in a vendor barrier room at 3-month intervals five times, and either shipped the next day (total time in transit ∼24 hr) or held in the room of origin until parturition. The pregnancy status, length of gestation, number of pups born per female, sex ratio of pups born, and neonatal mortality were compared between transported and nontransported rats. These pregnancy and litter parameters were also compared among strains and examined for seasonality; no seasonal effects were observed. Neonatal mortality was negligible at less than 2% in any of the groups. All sex ratios were normal. Transportation affected pregnancy rates only in the F344/Crl, in which 81.8% of the nontransported versus 70% of the transported rats had pups (p = 0.025). Overall, slightly fewer transported rats were pregnant, but they had larger litters (10.08 compared with 9.68, p = 0.02, pooling across all three strains) so produced the same numbers of pups. A total of 77 ± 8% of transported rats had gestation periods of 22 days or more compared with only 52 ± 10% in the nontransported rats. The reason for larger litters in transported females is unclear. Longer gestation in transported females may be due to facultative embryonic diapause, which might have implications for reproductive toxicology.</description></item></rdf:RDF>